# Oryzon Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oryzon-genomics

- Industry: Biotechnology
- Headquarters: Madrid, Spain
- Website: www.oryzon.com
- Total disclosed funding: $17M
- Latest round: Series B (Mar 6, 2008)
- Investors on record: 2

## About

Based in Madrid, Spain, and founded in 2000 by Chairmen Carlos Buesa, Oryzon Genomics S.A. operates as a biopharmaceutical company providing clinical-stage biopharmaceuticals that develops novel epigenetic therapies to treat oncology and neurodegenerative diseases. In November 2023, Oryzon Genomics SA raised venture funding from Nice & Green SA. 

Oryzon Genomics S.A. developed epigenetics-based therapeutics and medicines for treating cancer and neurodegenerative diseases. The company’s product has two drugs in Phase II clinical development such as iadademstat (also known as ORY-1001), a selective LSD1 inhibitor for oncology, and vafidemstat (also known as ORY-2001), a CNS optimized LSD1 inhibitor for CNS and psychiatric disorders. Its pipeline also includes another LSD1 inhibitor, ORY-3001, for the treatment of non-oncological diseases, ORY-4001, a selective HDAC6 inhibitor, and additional programs at earlier stages of development.

## Funding rounds

- Series B, Mar 6, 2008, $17M — Corsabe Capital, Ordesa Laboratories

## Investors

- Corsabe Capital (https://capitalatlas.ai/funds/corsabe-capital) — Series B
- Ordesa Laboratories — Series B